Drugdocs | Amlodipine and valsartan

Drug updated on 9/4/2024

Dosage Form	Tablet (oral; amlodipine/valsartan: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, 10 mg/320 mg)
Drug Class	Dihydropyridine calcium channel blockers and angiotensin II receptor blockers
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled on monotherapy.

Indicated for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Exforge (amlodipine and valsartan) is indicated for the treatment of hypertension to lower blood pressure in patients not adequately controlled on monotherapy and for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
Systolic and Diastolic Blood Pressure Reduction: Irbesartan/amlodipine ranked highest in systolic blood pressure reduction (SUCRA: 92.2%), while amlodipine/losartan ranked highest in diastolic blood pressure reduction (SUCRA: 95.1%).
Blood Pressure Control and Diastolic Response Rates: Telmisartan/amlodipine ranked first in blood pressure control rates (SUCRA: 83.5%), and amlodipine/losartan ranked first in diastolic response rate (SUCRA: 84.5%).
Amlodipine/valsartan was evaluated but no specific ranking or detailed effectiveness outcomes were provided for this combination.
There is no safety information available in the reviewed studies.
There is no population types or subgroups information available in the reviewed studies.

Document Title	Year	Source
Exforge (amlodipine and valsartan) Prescribing Information.	2021	Novartis Pharmaceuticals Corporation

Document Title	Year	Source
Efficacy of single-pill combination in uncontrolled essential hypertension: a systematic review and network meta-analysis.	2023	Clinical Cardiology